DNQX

Research use only, not for human use.

DNQX is a competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5 and 0.1 μM for AMPA and kainate receptors respectively).

DNQX is a competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5 and 0.1 μM for AMPA and kainate receptors respectively).

DNQX selectively depolarizes thalamic reticular nucleus (TRN) neurons.

DNQX, a specific AMPA receptor antagonist, given as either a 5 mg/kg or 10 mg/kg intraperitoneal dose or into the lateral cerebral ventricle (5 μl of 0.5 mg/ml) significantly diminishes phencyclidine (PCP) (40 mg/kg) and ketamine (80, 100, 120 mg/kg) hsp70 induction in the posterior cingulate and retrosplenial cortex.

FG 9041

Neuroscience

GluR

AMPA

——

——

2379-57-9

252.14

C8H4N4O6

>98% (HPLC)

DMSO:35 mg/mL (138.81 mM)

[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1[N+]([O-])=O

67-Dinitroquinoxaline-23(1H4H)-dione

(-20℃)

With Ice Pack

≥ 2 years